2023 was booming with novel psychiatric R&D and the promise of precision medicine for neuropsychiatric patients. Pipelines had gained momentum, with notable approvals on the horizon, as unmet needs in PTSD, bipolar, anxiety, schizophrenia, depression, and ADHD become greater and greater. Therefore, there had been a huge deal of novel and promising research to be discussed in October at the 6^th Neuropsychiatric Drug Development Summit.

Discovery, preclinical, translational, and clinical scientists from the likes of Biogen, Otsuka, AbbVie, Genentech, Lundbeck, Delix Therapeutics, Atai, Gilgamesh, and Cerevel Therapeutics had participated in the field’s favorite conference, specifically dedicated to biopharma’s most pressing challenges of de-risking the translational gap and advancing transformative neuropsychiatric candidates through the clinic.